Coherus Biosciences | CHRS - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Akebia Therapeutics USD -5.45M 9.4M 2025-12
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amarin USD -2.26M 564K 2025-12
Amgen USD 4.61B 777M 2026-06
Baxter International USD 276M 210M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Fujifilm JPY 101.76B 11.79B 2026-03
Gilead Sciences USD 3.85B 1.17B 2026-06
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Merck USD 840M 2.72B 2026-06
Myriad Genetics USD -3M 20.3M 2025-12
Pacira USD 9.96M 5.33M 2026-06
Perrigo USD 23.5M 10.1M 2026-06
Pfizer USD 667M 4.32B 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Teva Pharmaceutical Industries USD 235M 523M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06
Xencor USD -36.6M 41.26M 2026-06
Zoetis USD 1.12B 256M 2026-06